Medicxi is a London based life sciences venture capital firm dedicated to creating and investing in biotechnology companies across the full drug development continuum. With more than two decades of scientific and operational experience, the firm is known for its asset centric model, backing drug hunters and entrepreneurs who develop transformative therapies addressing clear unmet medical needs. Medicxi operates with a strong European presence, with additional offices in Geneva and St Helier.
Medicxi V is a €500 million fund backed by the firm’s existing limited partners and a select group of new institutional investors. The fund continues Medicxi’s strategy of supporting asset focused biotechnology companies and investing at all stages of development, from formation to late stage clinical programs.
The mandate of Fund V centers on identifying high potential therapeutic assets, supporting experienced drug hunters and enabling the creation of companies capable of advancing products through well defined milestones.
The fund also plans to invest in existing portfolio companies that align with Medicxi’s disciplined, asset centric value creation model.
Since its last fundraise, the firm has realized more than $1 billion across its portfolio through successful clinical outcomes, strategic acquisitions and public market activity.
Leadership
The investing partners for Fund V include Francesco De Rubertis, Giovanni Mariggi, Nick Williams and newly promoted Partner Shyam Masrani. The broader leadership team brings deep pharmaceutical, clinical development and biotechnology operating experience.
Investment Strategy
Medicxi follows an asset centric investment strategy built on identifying strong therapeutic concepts early and supporting them through key value inflection points. The firm partners closely with drug development experts and entrepreneurs, helping structure companies around clearly defined products, development plans and regulatory paths. The strategy emphasizes rigorous scientific diligence, capital efficiency and building companies designed for clinical validation and eventual commercialization or strategic acquisition.
Notable Investments
Medicxi has created 16 new biotechnology companies and delivered more than 20 positive clinical data readouts across its portfolio. Its investments include companies such as_
These companies reflect a history of advancing therapeutic assets through meaningful development milestones.
Notable Exits
The firm has realized significant portfolio value through acquisitions including:
Additional liquidity has been generated through portfolio company public listings and clinical successes.
Other
Fund V reinforces Medicxi’s long term vision of building and scaling high quality therapeutic companies that address real unmet medical needs.
Francesco De Rubertis - Partner
marie@medicxi.com (assistant)
Giovanni Mariggi - Partner
sarah@medicxi.com (assistant)
United Kingdom
